Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion

Abstract Background Mantle cell lymphoma (MCL) is a chronically relapsing malignancy with deregulated cell cycle progression. We analyzed efficacy, mode of action, and predictive markers of susceptibility to palbociclib, an approved CDK 4/6 inhibitor, and its combination with venetoclax, a BCL2 inhi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Diana Malarikova, Radek Jorda, Kristyna Kupcova, Jana Senavova, Alexandra Dolnikova, Eva Pokorna, Dmitry Kazantsev, Kristina Nozickova, Dana Sovilj, Celine Bellanger, David Chiron, Ladislav Andera, Vladimir Krystof, Miroslav Strnad, Karel Helman, Magdalena Klanova, Marek Trneny, Ondrej Havranek, Pavel Klener
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-03-01
coleção:	Experimental Hematology & Oncology
Assuntos:	Cyclin-dependent kinase (CDK) inhibitors Palbociclib BCL2 Venetoclax RB1 Mantle cell lymphoma (MCL)
Acesso em linha:	https://doi.org/10.1186/s40164-024-00499-2
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!